The Use of 5-Azacitidine in Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience  by Martin Lopez, Ana A. et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312S298collected from inpatient and outpatient charts in a de-iden-
tiﬁed manner. This study was approved by the institutional
review board of the University of Oklahoma Health Sciences
Center. Patient comorbidity index scores were calculated
within 30 days of transplant using the QxMD Hematopoietic
Cell Transplantation-Speciﬁc Index (HCT-CI) calculator. Kar-
nofsky Performance Status was determined by a physician
during pre-transplant assessment. Additional pre-transplant
data collected included: gender, age at transplant, date of
transplant, donor type, donor source, preparative method,
speciﬁc preparative regimen, disease status at the time of
transplant, disease type, and insurance status. Post-trans-
plant data collected included: survival at 100 days, 1 year,
and 2 years post-transplant, cause of death, presence of
graft-versus-host disease (GVHD), type of GVHD, organ
affected by GVHD, and documented infections. Our results
indicated that higher CMI scores were signiﬁcantly associ-
ated with increased non-relapse mortality in patients
undergoing myeloablative transplant preparative regimens
(P < .001). Lower KPS scores were also signiﬁcantly associ-
ated with poor survival ( P < .001). Insurance was not
signiﬁcantly associated with non-relapse mortality (P > .05).
Finally, 39% of all patient deaths were attributed to disease,
20% of patient deaths were attributed to non-relapse
mortality, while 41% of patients survived.377
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Introduction: Reduced intensity conditioning (RIC) with
alemtuzumab, ﬂudarabine, and melphalan improves the
hematopoietic cell transplant (HCT) outcomes of patients
with hemophagocytic lymphohistiocytosis (HLH). Proximal
dosing of alemtuzumab is associated with a high incidence of
mixed chimerism (MC) whereas distal dosing is associated
with less MC but higher incidences of acute GVHD following
initial graft infusion. We hypothesized that an intermediate
alemtuzumab schedule would optimize the incidences of MC
and acute GVHD.
Methods: Twenty-ﬁve consecutive transplants were per-
formed in patients with HLH or XLP using a RIC regimenwith
a novel intermediate alemtuzumab schedule of 1mg/kg
beginning on day -14. The cumulative incidences of MC and
acute GVHD were compared to 2 retrospective cohorts of
patients with HLH and XLP treated with distal (n¼15) or
proximal (n¼33) alemtuzumab schedules. All patients
received ﬂudarabine 150mg/M2 (1mg/kg if <10kg) divided
over days -8 to -4, and melphalan 140mg/M2 (4.7mg/kg if
<10kg) on day -3. Melphalan was reduced by 50% in one
infant due to concern for toxicity. GVHD prophylaxis con-
sisted of methylprednisolone and cyclosporine or tacrolimus
in all but 2 patients who received methylprednisolone and
MMF. Three patients additionally received methotrexate.
Results: The cumulative incidence of MC was less in the
intermediate alemtuzumab cohort at 34%, versus 72% in theproximal and 40% in the distal cohorts (P ¼ .008). The
cumulative incidence of acute GVHD related to initial graft
infusion (before MC) was 4% in the intermediate cohort and
0% in the proximal cohort (P ¼ .26), versus 13% in the distal
cohort (P ¼ .04, proximal versus distal). There was a trend
toward less overall acute GVHD (following graft infusion or
following intervention for MC) in the intermediate cohort
at 12%, versus 16% and 27% in the proximal and distal cohorts
(P ¼ .55).
Conclusion: This novel 14 day RIC regimen optimizes the
incidences of MC and acute GVHD.378
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Introduction: The allogeneic hematopoietic cell trans-
plantation (alloHCT) remains the only treatment modality
with known curative potential in MDS, AML and CMML. The
5-azacitidine is the ﬁrst line treatment in high-risk MDS that
are not suitable for intensive therapy. On the other hand,
there is not enough evidence for deciding which is the best
option, either 5-azacitidine or induction chemotherapy,
before alloHCT. In a similar way, the 5-azacitidine exposure
in post-alloHCT relapsemay be an attractive alternative, even
though there are not deﬁnite results yet.
Objective: Evaluate the capacity of 5-azacitidine in reducing
or stabilizing the disease before alloHCT, regarding associ-
ated toxicity, and its role in post-alloHCT relapses.
Patients And Methods: We retrospectively reviewed 36
patients who underwent alloHCT for high-risk MDS, AML
and CMML between October 2006 and September 2012 in
our center and who received 5-azacitidine before and/or
after alloHCT.
Results: 30 patients received 5-azacitidine pre-alloHCT, 22
were MDS (73%), 6 AML (22%) and 2 CMML (7%), with high-
risk cytogenetic (according to IPSS-R) in one third of them.
The median of cycles was 5 (1-12), using the conventional
dose and schedule, and presenting usual toxicity in only 38%
of cases. Two thirds of evaluable patients achieved complete
remission (CR) or partial response (PR) and 26% progressed.
83% of patients underwent alloHCT in some type of response
and 17% in progression. The alloHCT characteristics were:
median of age of 56 (35-67), peripheral blood as source of
stem cells in 93%, related donor in 62%, and reduced-inten-
sity conditioning in most cases (83%). At day +100, 82% of
patients achieved CR and 18% had progressed. The global
post-alloHCT relapse rate was 33%. The 2-years overall
survival (OS) and event-free survival (EFS) were 66% and 50%,
respectively. At 1 year, the relapse-free survival (RFS) was
65%, without having reached the median follow-up. We did
not observe any signiﬁcant statistical differences in OS after
taking into account the following factors: sex, diagnosis,
previous lines of treatment, response to 5-azacitidine,
response at alloHCT and type of donor. However, cytogenetic
risk did signiﬁcantly inﬂuence survival in terms of OS, EFS
and RFS, the same as source of stem cells, type of condi-
tioning regimen and response at day +100 in OS. 16 patients
received 5-azacitidine after post-alloHCT relapse with
a median of cycle of 3.5 (1-19), reduced dose in some cases
and limited toxicity (42%). The median of days after alloHCT
to the beginning of treatment was 152 (32-529). Two thirds
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43%.
Conclusion: The 5-azacitidine is a treatment modality that
can improve or stabilize the disease, allowing time for
patients to reach alloHCT, with little toxicity, and can induce
response after post-alloHCT relapses.Table 1














Week 2 -6.5 (56) -7.7 (23) -11.6 (26) -9.5 (37) -4.5 (49)
Week 4 -8.7 (46) -9.4 (19) -8.6 (25) -12.4 (31) -3.3 (44)
Week 6 -10.1 (35) -7.0 (13) -12.0 (22) -1.9 (24) 1.3 (33)
Week 8 -18.5 (36) -2.2 (12) -11.3 (19) 5.8 (18) 12.2 (31)*
Week 10 -15.4 (21) -7.3 (5) -15.6 (13) 5.7 (14) 6.1 (21)*
Post-Week 1 -13.3 (57) -5.8 (19) -2.8 (25) 8.8 (35) 7.7 (49)*
* P< 0.05 t-test versus placebo379
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Background: CMX001 is an orally bioavailable, broad spec-
trum, lipid acyclic nucleoside phosphonate converted inside
cells to the active antiviral, cidofovir diphosphate. In the
preclinical toxicology program, GI AEs (diagnosed as gas-
tropathy and enteropathy; dose-related changes included
ﬂattening or loss of epithelial cells lining the lumen of the
small intestine on chronic dosing) were dose-limiting after
daily administration; however, therewere no GI AEs or gross/
microscopic gut changes when animals were dosed twice-
weekly (BIW) up to 9 months. Radiolabel studies in mice
conﬁrmed that CMX001 concentrates in the gut mucosa
more than in other tissues. In a Phase 2 dose-escalation study
(CMX001-201; ClinicalTrials.gov identiﬁer: NCT00942305)
evaluating CMX001 for CMV prophylaxis in allogeneic
hematopoietic stem cell transplant (HSCT) recipients, an
increased rate of profusewatery diarrheawas seen at 200mg
BIW and was considered dose-limiting in this population. A
program-wide safety monitoring and management plan that
included an option for dose interruption ( 2 weeks) in
subjects with  Grade 3 diarrhea was introduced. Subse-
quently, few subjects ( 10%) discontinued therapy because
of GI AEs, indicating that dose interruption is an appropriate
strategy to manage CMX001-associated GI AEs and to ach-
ieve effective CMV suppression in this population.
Methods: Serum chemistry data were evaluated for changes
in SA, a well-established marker of protein loss, to assess the
potential relationship to diarrhea. Abnormally low SA
concentrations were tabulated and the lowest value identi-
ﬁed through +1 week post treatment. A clinically meaningful
SA decrease was deﬁned as value  30 g/L (lower limit of
normal 33 g/L) and  4 g/L lower than baseline.
Results: Increased grade and/or duration of diarrhea corre-
lated with the decrease in SA concentrations over time as
shown in the Kaplan-Meier plots with data grouped by “low”
( 100mg/week) and “high” ( 200mg/week) CMX001 dose
vs. placebo. To rule out GI-GVHD (a common cause of diar-
rhea in HSCT recipients), the SA data from solid organ
transplant (SOT) patients treated with CMX001 in an
expanded access study (CMX001-350; ClinicalTrials.gov ID:
NCT01143181) were also evaluated. A similar timing of
decrease in SA concentrations was seen in these subjects
who are unlikely to have GVHD; urinalysis data also excluded
proteinuria as a cause.
Conclusions: Our clinical experience in the HSCT population
is consistent with preclinical ﬁndings. On chronic dosing,
CMX001 likely accumulates in the gut mucosa in some
patients and causes diarrhea that may be more pronounced
in individuals with other causes of diarrhea (eg, GI-GVHD).
Dose interruption gives the gut mucosa time to recover,
allowing subjects the opportunity to resume therapy.Monitoring SA changes in patients may provide an early and
objective indicator of potential drug-related GI AEs.380
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Background: CMX001 is an orally bioavailable, broad spec-
trum, lipid acyclic nucleoside phosphonate converted intra-
cellularly into the active antiviral, cidofovir diphosphate.
Unlike cidofovir, CMX001 is not a substrate for the anion
organic transporter and therefore is not concentrated in the
kidney.
Methods: Study CMX001-201 was a 9-11 week randomized,
placebo-controlled, double-blind, dose-escalation study
(evaluating 40 mg weekly [QW], 100 mg QW, 200 mg QW,
200mg twice-weekly [BIW] and 100mg BIW) of CMX001 for
the prevention of CMV infection post-HCT (ClinicalTrials.gov
ID: NCT00942305). Treatment was initiated at the time of
engraftment and continued until Week 13 post-HCT. Results
presented elsewhere have shown that CMX001, at various
doses, was active andwell tolerated in the prevention of CMV
infection or disease. Renal safety was assessed throughout
the duration of therapy using serum creatinine, urinalysis
and estimated glomerular ﬁltration rate (GFR, MDRD4
formula).
Results: 230 subjects were enrolled in the study; 59
received placebo and 171 received CMX001 at various
doses. 24 subjects (41%) on placebo and 77 subjects on
CMX001 (45%) had BK viruria prior to dosing. One subject
discontinued CMX001 40 mg QW due to acute renal failure;
no other subject discontinued from the study due to renal
adverse events. Results of calculated GFR by Study Cohort
and over time are presented in Table 1 below. Overall, renal
function tended to decline in placebo recipients while renal
function appeared to improve in subjects who received
CMX001 at 200 mg per week (either QW or divided into
2 BIW doses). The renal function decline in placebo
recipients appeared to be associated by the presence of
BK virus (BKV) in the urine at the time of treatment
commencement, while the proportion of subjects with
renal dysfunction was similar between BKV positive and
negative subjects among CMX001 recipients. There was
also a decreased incidence of microscopic hematuria in
BKV infected subjects treated with CMX001 as compared
to placebo recipients (6% vs. 25%).
Conclusions: CMX001 when administered at doses of 200
mg per week is not associated with signs of nephrotoxicity
